AMPH Amphastar Pharmaceuticals, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Amphastar Pharmaceuticals, Inc. (AMPH) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on November 6, 2025, an 8-K current report filed on March 16, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Amphastar Pharmaceuticals, Inc. (AMPH) (SEC CIK 1297184), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 8.01: Other Events
- • Board authorized $50M increase to existing share buyback program on March 12, 2026
- • Program runs indefinitely; primary purpose is offsetting dilution from equity compensation, not aggressive capital return
Item 1.01: Entry into a Material Definitive Agreement
- • Supply Agreement with Letop (March 3, 2026): ANP sources chemical intermediates; 5-year term, no minimum purchase obligation, payments in Chinese yuan
- • Related party risk: Letop majority-owned by Henry Zhang, son of CEO Dr. Jack Zhang and COO Dr. Mary Luo — Audit Committee approval required and obtained
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • Liawatidewi (EVP Corporate Admin, Secretary, Board member): $525,800 base salary + 55% target bonus
- • Zhou (Sr. EVP Production): $590,000 base salary + 53% target bonus
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Amphastar Pharmaceuticals, Inc. (AMPH) 8-K current reports disclosing material events.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
8-K | Mar 16, 2026 | — | Analysis | — |
8-K | Mar 6, 2026 | — | Analysis | — |
8-K | Mar 6, 2026 | — | Analysis | — |
8-K | Feb 26, 2026 | — | Analysis | — |
10-K | Feb 26, 2026 | Dec 31, 2025 | — | |
8-K | Jan 12, 2026 | — | — | |
10-Q | Nov 6, 2025 | Sep 30, 2025 | — | |
10-Q | Aug 7, 2025 | Jun 30, 2025 | — | |
10-Q | May 8, 2025 | Mar 31, 2025 | — | |
10-K | Mar 3, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 9, 2024 | Jun 30, 2024 | — | |
10-Q | May 10, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 8, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 9, 2023 | Jun 30, 2023 | — | |
10-Q | May 9, 2023 | Mar 31, 2023 | — | |
10-K | Mar 1, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 8, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 9, 2022 | Jun 30, 2022 | — | |
10-Q | May 10, 2022 | Mar 31, 2022 | — | |
10-K | Mar 11, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 9, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 9, 2021 | Jun 30, 2021 | — | |
10-Q | May 7, 2021 | Mar 31, 2021 | — |
Frequently Asked Questions
What are the latest AMPH SEC filings in 2026?
Amphastar Pharmaceuticals, Inc. (AMPH) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 6, 2025, an 8-K current report on March 16, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did AMPH file its most recent 10-K annual report?
Amphastar Pharmaceuticals, Inc. (AMPH) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view AMPH 10-Q quarterly reports?
Amphastar Pharmaceuticals, Inc. (AMPH)'s most recent 10-Q quarterly report was filed on November 6, 2025. SignalX displays every AMPH 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has AMPH filed recently?
Amphastar Pharmaceuticals, Inc. (AMPH)'s most recent 8-K was filed on March 16, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find AMPH insider trading activity (Form 4)?
SignalX aggregates every AMPH Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does AMPH file with the SEC?
Amphastar Pharmaceuticals, Inc. (AMPH) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new AMPH filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Amphastar Pharmaceuticals, Inc. (AMPH).
What is AMPH's SEC CIK number?
Amphastar Pharmaceuticals, Inc. (AMPH)'s SEC CIK (Central Index Key) number is 1297184. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1297184 to look up all AMPH filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find AMPH return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Amphastar Pharmaceuticals, Inc. (AMPH) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Amphastar Pharmaceuticals, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 52+ filings.